Topline Phase 1 Trial Results for Apogee’s APG777 in AD “Exceed Expectations”
The Dermatology Digest
MARCH 5, 2024
Pharmacokinetic (PK) data showed a half-life of approximately 75 days across doses tested and pharmacodynamic (PD) data showed, deep and sustained inhibition of key atopic dermatitis (AD) biomarkers pSTAT6 and TARC for ~3 months (longest follow-up available, with inhibition still ongoing at time of the data cut).
36 
Let's personalize your content